3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Neoplasms
10
Carcinoma, Renal Cell
8
Carcinoma, Hepatocellular
8
Melanoma
7
Carcinoma, Non-Small-Cell Lung
7
Endometrial Neoplasms
6
Thyroid Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Recurrence
4
Thyroid Cancer, Papillary
3
Stomach Neoplasms
3
Neuroendocrine Tumors
3
Colorectal Neoplasms
3
Adenocarcinoma, Follicular
3
Ovarian Neoplasms
2
Osteosarcoma
2
Neoplasm Metastasis
2
Lymphoma
2
Lung Neoplasms
2
Glioma
2
Carcinoma, Transitional Cell
2
Carcinoma
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid cancer, medullary
1
Thyroid cancer, Hurthle cell
1
Thyroid Diseases
1
Thyroid Carcinoma, Anaplastic
1
Interventions
Trastuzumab
3
Sugammadex
2
Neostigmine
2
Cisplatin
2
valrubicin
1
tucatinib
1
pembrolizumab
1
niraparib
1
enfortumab vedotin
1
avelumab
1
atezolizumab
1
Surveys and Questionnaires
1
Sunitinib
1
Standard of Care
1
Rocuronium
1
Pemetrexed
1
Paclitaxel
1
Nephroureterectomy
1
Neoadjuvant Therapy
1
Mitomycin
1
Lymph Node Excision
1
Glycopyrrolate
1
Gemcitabine
1
GSK-3326595
1
Fulvestrant
1
Docetaxel
1
Cetuximab
1
Afatinib
1
Administration, Intravesical
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Urologic Neoplasms
×
lenvatinib
×
Clear all
No trials found.